Lisata Therapeutics IncLSTA
Price$1.49

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $100K-90.0% YoYTTM through 30 Jun 2026
Net Income -$14.6MTTM through 30 Jun 2026
Free Cash Flow -$12.3MTTM through 30 Jun 2026

Margins

Current
Operating Margin-10,711.2%
Net Margin-14,621.0%

Returns

-111.7%ROE
-93.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio5.76x
Net Debt-$16Mnet cash position
Cash & Equivalents$10.4M

Quality Metrics

Altman Z-Score-73.50
Piotroski F-Score2 / 9
FCF Margin-12,323.0%
Earnings-Beat Rate66.7%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $170K
Diluted EPS-$1.64TTM
'18'20'21'22'23'24'25
FY2025: $-1.91

Dividend

No dividend

Capital Allocation

Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.